As filed with the Securities and Exchange Commission on July 12, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTELLIGENT BIO SOLUTIONS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) Delaware 3829 82-1512711 142 West 57 ...

As filed with the Securities and Exchange Commission on June 23, 2023 Registration No. 333-272463 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 TO Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTELLIGENT BIO SOLUTIONS INC. (Exact name of registrant as specified in its charter ...

As filed with the Securities and Exchange Commission on June 6, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTELLIGENT BIO SOLUTIONS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) Delaware 3829 82-1512711 142 West 57 S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 (Sta ...

Acquisition and Expansion - The company completed the acquisition of Intelligent Fingerprinting Limited (IFP) on October 4, 2022, expanding its portfolio of rapid, non-invasive diagnostic testing technologies[168]. - The IFP acquisition involved issuing 2,963,091 shares of common stock and 2,363,003 shares of Series C Convertible Preferred Stock as consideration[169]. - IFP expanded its customer base by entering sales contracts with several UK companies, including Glass Systems and Eastern Airways[180]. - The company aims to increase market share in the UK and West Europe while commencing distribution in the Asia region and pursuing FDA regulatory approval for the US market[175]. Financial Performance - Revenue from sales of goods increased from $0 to $356,679 for the quarter ended December 31, 2022, compared to the same period in 2021, due to the acquisition of Intelligent Fingerprinting Limited (IFP) during the current quarter[199]. - Gross profit for the quarter ended December 31, 2022, was $244,044, with total operating expenses of $2,644,636, resulting in a loss from operations of $2,130,967[198]. - The net loss for the quarter ended December 31, 2022, was $427,071, compared to a net loss of $3,463,823 for the same period in 2021[198]. - The total comprehensive loss for the six months ended December 31, 2022, was $1,415,111, compared to a comprehensive loss of $4,961,790 for the same period in 2021[198]. - Cash and cash equivalents as of December 31, 2022, were $2,911,682, with working capital of $1,563,530[226]. - The company expects its cash and cash equivalents will be insufficient to fund its current operating plan for at least the next twelve months[227]. Research and Development - The company is developing a Saliva Glucose Biosensor (SGB) to replace invasive blood glucose monitoring for diabetic patients, with ongoing clinical studies involving 40 adult subjects[174]. - The Saliva Glucose Test (SGT) is expected to substitute invasive blood glucose monitoring for diabetic patients, utilizing a non-invasive method to measure glucose levels in saliva[188]. - The Biosensor Platform Technology allows for the detection of multiple biological analytes, with the potential to develop tests for cancer biomarkers and hormones[197]. - The SGB (Saliva Glucose Biosensor) can detect glucose in saliva at concentrations between 8 and 200 µM, exhibiting sensitivity 100 times lower than blood glucose levels[190]. - The company has completed the development of an intermediate device that communicates with smart devices, enhancing the functionality of the SGB[194]. - The company is developing an R&D and manufacturing facility at the University of Newcastle, Australia, with construction expected to start in Q2 2023[180]. Stock and Shareholder Information - A reverse stock split at a ratio of 1-for-20 became effective on February 9, 2023, reducing the number of outstanding shares from approximately 18.3 million to about 916,265[178]. - The company has reserved up to 1,649,273 shares of Series C Preferred Stock for potential future issuance related to the IFP acquisition and employee stock options[170]. - The weighted average shares outstanding for the quarter ended December 31, 2022, was 908,283, compared to 744,126 for the same period in 2021[198]. Government Support and Expenses - The company reported government support income of $269,625 for the quarter ended December 31, 2022, compared to $177,791 for the same period in 2021[198]. - General and administrative expenses increased by $1,242,045 to $2,245,289 for the quarter ended December 31, 2022, compared to $1,003,244 in the same period in 2021, largely due to the acquisition of IFP[207]. - Development and regulatory expenses decreased by $2,639,991 to $1,191 for the quarter ended December 31, 2022, compared to $2,641,182 in the same period in 2021[210]. - Government support income in the IFPG and SGBP segments increased by $91,834 to $269,625 for the quarter ended December 31, 2022, compared to $177,791 in the same period in 2021[203]. Other Financial Metrics - The outstanding fair value of convertible notes as of December 31, 2022, was $523,703, with an interest rate of 17% per annum[230]. - Unrealized foreign currency translation gain increased by $354,242 to $361,597 for the quarter ended December 31, 2022, compared to $7,355 in the same period in 2021[221]. - Net loss attributable to INBS decreased by $3,039,398 to $420,600 for the quarter ended December 31, 2022, compared to $3,459,998 in the same period in 2021[223].

Financial Data and Key Metrics Changes - As of September 30, 2022, the company's cash, cash equivalents, and marketable securities totaled approximately $5.74 million, down from approximately $8.24 million on June 30, 2022, primarily due to expenditures related to the proposed pilot manufacturing facility in Newcastle and exchange rate losses [31][32] - For the year ended September 30, 2022, the company reported a preliminary net loss of $1.21 million or $0.08 per share, compared to a net loss of $1.43 million or $0.10 per share for the same period last year, reflecting a decrease in loss due to government support income recognized in the current period [32][33] Business Line Data and Key Metrics Changes - The acquisition of Intelligent Fingerprinting Limited (IFP) is expected to enhance the company's capabilities in on-site diagnostic testing, with IFP's technology focusing on drug testing using fingerprint sweat [11][15] - The company is progressing with its biosensor product, a non-invasive saliva-based glucose testing solution, with clinical studies underway to optimize testing methods and assess accuracy [16][17] Market Data and Key Metrics Changes - The global drug testing market is estimated to be approximately $4.6 billion as of 2023, with a compound annual growth rate of 5.6%, and the U.S. market is expected to comprise about 75% of this total [24] - The company aims to expand IFP's product line into the U.S. point-of-care workplace market, requiring FDA commercial accreditation, with initial interactions deemed favorable [25][26] Company Strategy and Development Direction - The company is focused on leveraging IFP's technology to expand into new markets, including Australia and the U.S., with plans to replicate successful strategies from the U.K. [39][42] - The management team is committed to integrating IFP's operations and exploring additional diagnostic applications for fingerprint testing beyond current drug testing capabilities [28][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the acquisition of IFP as a significant step forward, enhancing commercial manufacturing and regulatory capabilities [13][14] - The company anticipates strong growth in client base and market demand for non-invasive testing solutions, particularly in diabetes and substance abuse [62] Other Important Information - The company plans to switch to a December 31 calendar year for reporting, with the next earnings release expected to include full financials for 2022 incorporating IFP [34] - The construction of a state-of-the-art manufacturing facility at the University of Newcastle, Australia, is anticipated to commence before the end of 2022 [19] Q&A Session Summary Question: Initial efforts in Australia and New Zealand with IFP - The company expects to start sales in the first quarter of 2023, focusing on providing an end-to-end solution for on-site testing [38][40] Question: Follow-on regions for expansion - The U.S. market is a primary focus, representing 75% of the overall market, with significant interest from various regions globally [42][44] Question: U.K. police force project - There is significant interest from the U.K. police regarding drug testing solutions, which could become a substantial revenue generator [45][48] Question: Manufacturing facility and grant funding - Grant funding is milestone-based, with cash flows expected as milestones are achieved [50][52] Question: Market for cortisol testing - The company is currently analyzing the market for cortisol testing and believes there is substantial potential [53][55] Question: Saliva blood correlation study publication - Results from the clinical trials are expected to be publicized in late Q1 or early Q2 of the following year [56]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 GBS Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 (State or other jurisdiction of inc ...

GBS, Inc. (GBS) Q4 2022 Earnings Conference Call August 31, 2022 4:30 PM ET Company Participants Steven Boyages - Chairman and Interim CEO Spiro Sakiris - CFO Conference Call Participants John Vandermosten - Zacks SCR Operator Greetings, and thank you for joining us for GBS, Inc's Fourth Quarter and Fiscal Yearend 2022 Financial and Business Update Conference Call. Currently all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, today's ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 GBS Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 (State or other jurisdicti ...